Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
 
Register now or login to post to this thread.

Osmetech : The Next Generation - Info and Links thread. (OMH)     

DITCHPIG - 30 Apr 2004 15:09

omhnew4vo.gifomhlogo24kn.gifomhnew4vo.gifomhbot8kj.gif

UBS AG buy 8,825,000 6.7%

eSensor LAUNCHED!!!

FDA clearance for Cystic Fibrosis DNA Test

Sales of the eSensor instrument and CF test will commence in the first half of 2006 as planned.. .

James White, CEO of Osmetech said:

'Gaining FDA clearance for our first microarray based test developed for our new eSensorTM molecular diagnostics instrument is a major step forward for our Molecular Diagnostics Division and will help to establish Osmetech as a key player in the fast growing moleculardiagnostics market. In addition, this FDA clearance helps to validate our microarray technology for routine use in the laboratory.

Critical Care DivisionThe Division has a strong product portfolio and is well placed to continue the growth of instrument placements throughout the world, leading to revenues from proprietary consumables for a number of years to come.Sales of OPTI instruments and consumables remained strong resulting from increased sales of the new touchscreen version of the long-established OPTI (CCA). In 2006 we will start to see an important contribution to sales from the new OPTI LION portable electrolyte analyser and the OPTI R blood gas and electrolyte analyser with reusable consumable as these products are rolled out internationally.'

Molecular Diagnostics DivisionFollowing FDA approval of the eSensorTM platform Osmetech are now looking to progress discussions with strategic partners who are looking for cost effective and easy to use instrumentation and consumables to work on other complex assays both in the healthcare and non healthcare markets. The next Osmetech Molecular test targeted for FDA submission will be the CYP 450 pharmacogenomics assay, which is currently in development.

James White, CEO of Osmetech commented:

'We have been delighted with the rapid integration of the CMS business acquired in July. The powerful combination of the eSensor product together with OPTI GENE provides Osmetech Molecular Diagnostics with an excellent position in this rapidly developing and growing market sector. Both products remain on schedule for launch and revenue generation in the first half of 2006'

Sales to year end up over 40%

Osmetech has reported a strong rise in sales in the latter part of 2005 with growth driven byabove-forecast revenues at its Critical Care blood gas analysis division.. Sales for the Critical Care division in calendar year 2005 exceeded $14.7m, representing an increase of over 60% compared to the calendar year 2004. Approximately half of this overall growth is due to sales to veterinary distribution partner, IDEXX Laboratories, Inc.

Vetstat Exceeds Idexx Expectations

Sales of the VetStat electrolyte and blood gas analyser have been very encouraging and continue to exceed expectations. IDEXX's sales successes and continuing marketing efforts should result in further strong growth for the foreseeable future. As the installed base of instruments becomes established, revenues from proprietary consumables are expected to increase as a proportion of this veterinary business. Following a deal with leading US vetinary hopsital chain Banfield, Idexx are contracted to supply an additional 450 Vetstat devices over the coming year.Good progress is also being made with IDEXX on the development and supply contract to create a new platform for measuring critical care parameters based on Osmetech's proprietary optical fluorescence technology and consumables. It is anticipated that this market leading product is on target for launch late 2006/2007.

Critical Care Product Range - In Production

OPTI-CCA Opti CCA. Sales revenues for this product and consumables were in excess of $14,000,000 in 2005. More than 5000 units are in use worldwide.OPTI-LION Opti Lion. Newly launched in late 2005 this device competes head on with more complex systems. Significant sales are forcast for 2006/7OPTI-R Opti R. Newly launched in late 2005 the OPTI R is a compact blood gas analyzer using a combination of proven maintenance-free sensor technology, intuitive graphic user interface and automated system monitoring to increase operator convenience and reduce time spent on blood gas testing while delivering fast reliable results.OPTI-2L Opti 2 Line. Designed for portability, the Osmetech OPTI Analyzer is always ready for testing wherever you need it for measurement of pH/blood gas, total hemoglobin, oxygen saturation, electrolytes and glucose.

Critical Care Consumable Product Range - In Production

SamplerComfort Sampler. Launched in July 2004 this product, has become the arterial blood sampling method most preferred by therapists and patients. Sales are expected to generate revenues in excess of $2,000,000.Cassette Sensor Cassette. Over 4000 tests per day are made using Opti consumables generating revenues in excess of $8,000,000Callibration The calibration gas bottle assures accurate calibration prior to each sample measurement.DataTrolData Management Software. Consolidate test results in one centralized location

Molecular Diagnostics Product Range - In Production

Opti-GeneOpti-Gene. The system allows for the detection of DNA and RNA targets using PCR or RT-PCR based assays in hospital and clinical research laboratories. Lauching in May first test will be for Factor V Leiden MutationeSensoreSensor. a low cost instrument and consumable for moderately complex genetic testing where the detection of multiple gene targets is required. Initally tests will be for cystic fibrosis and CYP450.BiochipBiochip. Single use bio-chip disposable cartridge for use in the eSensor device.ConsumableConsumables. Disposable cartridge for use in the eSensor device.OPTI Tube OPTI Tube Primary consumable for the OPTI Gene and compatible with the large installed base of LightCycler instrument. Launching from May

Product Range - Licenced to Third Party

VetStat VetStat Based on the OPTI-CCA device. This instrument is being sold in to the vetinary market by industry leading corporation IDEXX. Considerable sales are being made Cassettes Cassette : The only blood gas system calibrated for veterinary-specific reference ranges. An increasing range producing substantial sales. Being sold by Idexx for the Vetstat deviceOPTI Tube OPTI Tube Licensed to Roche to manufacture and sell plastic consumable vials for use on its large installed base of LightCycler instruments. Osmetech plans to manufacture and sell the plastic consumable vials as an alternative to glass vials itself. Sales are anticipated to start early 2006 AVOX 4000 AVOX 4000 The AVOXimeter 4000 provides a fast, accurate assessment of patient oxygenation at the bedside. Sold worldwide (-usa) by Osmetech in a deal with Avox

Buisness Partners
idexxlogo.gifroche_logo.giflogo.gifsysmex_logo.jpg

Major Shareholders
Organisation Shareholding % Gartmore 24,109,657 18.29% Schroder 18,874,284 14.32 UBS AG 8,825,000 6.70TD Waterhouse 7,011,137 5.32 Barclays Nom 6,638,092 5.04 Pershing Keen 5,870,773 4.45HSBC Global Nom 6,544,718 4.97 Roche 2,444,688 1.8 Marlborough UK Micro Cap Director Holdings James White 208,092 Gordon Hall 104,966 D Sandilands 61,597 GB Kuenster 33,054 A Marek 26,190 ADVFN Posters 5,896,564 4.5 Total Holdings 86,648,812 65.7%

Mouse Over Images For Product Data
backup_counter.cgi?counter_id=644347updater.cgi?counter_id=644347&increment=If regular posters would like to be included in the ADVFN figure and if you are not bothered about the figures being public then post your long-term holding here.IE the number of shares you intend to keep for say more than 6 months?Alternatively if you'd rather keep your holdings secret but still want contribute to the overall figure then drop me a line to ditchpig@ntlworld.com

DITCHPIG - 21 Jan 2005 11:33 - 143 of 242

yip!!!

bangersmam - 21 Jan 2005 14:34 - 144 of 242

Looking very strong now, rising on heavy volume. Seems both MM's EVO & WINS are trying to fill orders, pushing the price up in their competition.

babykitcat - 21 Jan 2005 14:40 - 145 of 242

keep it up

babykitcat - 21 Jan 2005 16:23 - 146 of 242

10:29am 900,000 sale (OR WAS IT!!!!)

DITCHPIG - 21 Jan 2005 16:32 - 147 of 242

a 900k sale wouldn't put the price up!

babykitcat - 21 Jan 2005 16:38 - 148 of 242

precisley not right all this market making is it really!!!! all i say is just wait till share starts to go on a roll and we not be making post's like this

babykitcat - 23 Jan 2005 21:37 - 149 of 242

DP been looking @ various web sites and i notice you have made your own for this company looks nice you seem to be very much into this company good on you i been waiting 5 years for this the grow

DITCHPIG - 24 Jan 2005 08:19 - 150 of 242

Well someone has got to make a stand BK. Osmetech seem determined not to publicies themselves so if I make a bit of an effort and it gets a few more people on board all the better. After all we all benefit and hopefully it bugger up evil EVos plans.

L2 is looking strong this morning.
Only SCAP on the offer at 3.75. Next stop scap at 3.8 then we have 5 MM on 4p or more. That's 1 more than friday.
On the bid side Evo and MLSB lead the pack on 3.7 with Wins next on 3.65.
A decent bit of buying could see us push through 4p today.

babykitcat - 24 Jan 2005 08:34 - 151 of 242

great but knowing this one it will go DOWN!!!!
you do much trading on this (7 days) or do u hold

DITCHPIG - 24 Jan 2005 08:45 - 152 of 242

Windys160,
Thanks for your input. Interesting what DW had to say. Atleast it confirms we will see something about Idexx in the results. Which can only be good. I wonder how much of an upfront payment Osmo got from Idexx for developing it?

DITCHPIG - 24 Jan 2005 08:51 - 153 of 242

BK . Only ever take a trading position to provide a bit of pocket money leading up to the results. Took 250ks worth a couple of weeks a go. The rest of my holding stays put currently got 1.8 million built up over 3 years for the long term. This baby is going to allow me to retire early.
Hopefully.

babykitcat - 24 Jan 2005 08:52 - 154 of 242

MY THOUGHTS ENTIRLEY nice tight spread looking good

DITCHPIG - 24 Jan 2005 09:07 - 155 of 242

Spread pretty tight, no movement on L2 yet. L2 has its uses for non sets stocks just a shame it does not tell you how many the MM have got left to sell before they move up.
Scap are holing us back at 3.75. Depends how impatient EVO get. We may see a micro move up so EVO can go top of the back again.

babykitcat - 24 Jan 2005 09:12 - 156 of 242

just had a little top up

bangersmam - 24 Jan 2005 09:32 - 157 of 242

Nice one Kitkat, i recon you timing could be pretty good. All we need is a few fair sized buys and this IMO will move fast!

DITCHPIG - 24 Jan 2005 09:39 - 158 of 242

KBC have now joined EVO and MLSB on the bid at 3.7 This will place more pressure on Evo to move up. Now 6mm sat at 4p and above.
Only scap spoiling the fun at 3.75 but given the buys so far today they can not stay there all day. When they've gone we'll see a big jump to 4p on the offer

babykitcat - 24 Jan 2005 09:41 - 159 of 242

thank please keep me posted

babykitcat - 24 Jan 2005 11:57 - 160 of 242

and they DO look like sells aswell not mm playing bat & ball

DITCHPIG - 25 Jan 2005 10:24 - 161 of 242

I think most of us have been stiched up by EVO and the MM's games over the last couple of years, the real enemy is not each other it is EVO and the MM's. They are the fools we need to be making money off rather than giving it to them. This share needs people with balls of steel, you have to ride out the rough with the smooth, the ups and down and the pumps and dumps.
Study the company, look long and hard at what they are doing and how they are doing it. Look at the way Osmetech has transformed itself in the last 18 months. Look at the fundementals, look at the potential market for their products look at what the management have done to safe guard the long term future of the company.
Buying OPTI and MOLS were a strokes of genius and the company is still looking for similar deals. Despite all the knockers both on here and III Jimmy boy and co have done a great job stream lining the company and getting it focussed.
VIP5 and GENEDRIVE are going to be the real cash cows are a within 12 months of being launched. Osmetech will then have dipped two toes into a two multi billion dollar markets. By listening to the derampers and the notsoHOT pump and dump merchants now you could be kicking yourself in 18 months time.

Buy your shares and hold the bloody things. Don't sell them back to EVO at the first sign of a tree shake. EVO are well aware of what the future holds, why would they have backed Osmo financially if they did not? EVO will be hanging in to the glory days and so should you.
Become a TRUE INVESTOR Buy your thousand quids worth of shares and hold on to them through thick and thin.
18 Months from now I am sure you will be more than amply rewarded.
Have you got balls of steel or testicals of tissue?

babykitcat - 25 Jan 2005 11:03 - 162 of 242

good point im in long term 2 yrs and i want results
Register now or login to post to this thread.